Nichi-Iko Aims For ‘Commanding Presence’ In Japan Generics Via Eisai Alliance

 
• By Ian Haydock

Eisai has become the latest R&D-based pharma company in Japan to offload its non-innovative products as it seeks to maximize their sales and focus more on novelty and, by implication, the rewards this can bring under Japan’s evolving reimbursement pricing system.

businessman and businesswoman are exchanging document or contract
EISAI OFFLOADS JAPAN GENERICS BUSINESS TO NICHI-IKO

More from Japan

More from Focus On Asia